Flexion Therapeutics (FLXN)

Flexion Therapeutics (FLXN) is a specialty pharmaceutical company developing an anti-inflammatory and analgesic injection for the treatment of patients with osteoarthritic pain. FLXN’s lead candidate currently in phase 3 trials is FX006, a sustained-release intra-articular steroid (triamcinolone acetonide) for patients with moderate to severe osteoarthritis (OA) pain.

Published Reports

FLXN 4Q18 rev
FLXN guidance rev
FLXN SHIP rev
FLXN SHIP rev
FLXN 3Q18 rev
FLXN-2Q18-rev.pdf
FLXN 1Q18 rev
FLXN Q Code rev
FLXN 4Q17 rev
FLXN Zilretta approval rev
FLXN ndr rev
FLXN 2Q17 rev
FLXN Zilretta PDUFA
FLXN 1Q17 rev
FLXN 4 3 17 ndr rev_JFM edits rev (1)
FLXN 4Q16 rev
flxn-3q16-rev_jfm-edits-rev
FLXN FDA 5.26.16 rev
FLXN kol  5.19.16 rev
FLXN 1Q16 rev
FLXN_OARSI data.4.4.16 rev
FLXN.phase 3 data.2.17.16 rev
FLXN.3Q15 rev
FLXN.ManagementDay.10.27.15-rev
FLXN phase 2b first look 9 8 15
FLXN FastTrack 9 1 15 rev
FLXN.KOL call.8.21.15 rev
FLXN 2Q15 8 7 15 rev
FLXN.1Q15.5.7.15 rev
FLXN initiation